Supplementary Figure S1 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Supplementary Figure S1. Tumor volume in CD49d+ and CD49d− CLL during acalabrutinib treatment
Supplementary Figure S1 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy. | Synapse